Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 11/20 | 0.58 |
| ▸ | ESR1 | P03372 | 10/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11827 | 0.83 | DYRK1A (0.56) | ESR2ESR1CA2HSD17B1HTT | |
| SCHEMBL422041 | 0.77 | HDAC3 (0.52) | ESR2ESR1GAADYRK1ACYP1A2 | |
| SCHEMBL28145858 | 0.77 | ESR1 (0.59) | ESR2ESR1CA2HSD17B1HTT | |
| SCHEMBL8268409 | 0.74 | APP (0.36) | ESR2ESR1 | |
| SCHEMBL144486 | 0.74 | ALDH1A1 (0.38) | ESR2ESR1HTTGAADYRK1A | |
| SCHEMBL31009687 | 0.74 | CYP2A6 (0.38) | HTTDYRK1ACYP1A2 | |
| SCHEMBL10369249 | 0.74 | ESR1 (0.55) | ESR2ESR1CA2HSD17B1HTT | |
| SCHEMBL3962610 | 0.74 | CYP2A6 (0.38) | HTTDYRK1ACYP1A2 | |
| SCHEMBL147786 | 0.74 | GFER (0.41) | HTTDYRK1ACYP1A2 | |
| SCHEMBL5740193 | 0.74 | ESR1 (0.55) | ESR2ESR1CA2HSD17B1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285819-A | Benzoxazole compound and application thereof | 江苏恩华药业股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| CN-101508691-A | Sulphaminic acid benzothiophene ester derivative used as steroid sulfatase restrainer | THERAMEX SAM LAB (MC) | 2009-08-19 | — | — | CN | disclosed |
| CN-100491370-C | Benzothiophenesulfonate derivatives as steroid sulfatase inhibitors | THERAMEX (MC) | 2009-05-27 | — | — | CN | disclosed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101157683-A | Sulfatase inhibiting agent | THERAMEX (MC) | 2008-04-09 | — | — | CN | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1515975-B1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| WO-2005048922-A2 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1515975-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-6869962-B2 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | ESR2 4064/4885ESR1 3836/4885CA2 2125/4885 |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | MB, ALB, BCAT2 | ESR2 3041/4885ESR1 2128/4885CA2 1988/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | ESR2 4064/4885ESR1 3836/4885CA2 2125/4885 |
| US-20060079548-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | TPD52L2, DPYD, CCND2 | ESR2 4115/4885ESR1 3213/4885CA2 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.